Journal
CANCER SCIENCE
Volume 111, Issue 9, Pages 3122-3131Publisher
WILEY
DOI: 10.1111/cas.14517
Keywords
biomarker; cancer; MiR-145; therapeutic resistance; Therapeutic sensitivity
Categories
Funding
- National Key Research and Development Program of China [2016YFC0905900]
- Jiangsu Provincial Key Research Development Program [BE2019731]
- National Natural Science Foundation of China [81872365]
Ask authors/readers for more resources
MircoRNA (miRNA) are a group of small, non-coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post-transcriptionally through complementary binding to the 3MODIFIER LETTER PRIME-untranslated region (3MODIFIER LETTER PRIME-UTR) of multiple target genes. Emerging evidence has shown that miRNA are frequently dysregulated in a variety of human malignancies. Among them, microRNA-145 (miR-145) has been increasingly identified as a critical suppressor of carcinogenesis and therapeutic resistance. Resistance to tumor therapy is a challenge in cancer treatment due to the daunting range of resistance mechanisms. We reviewed the status quo of recent advancements in the knowledge of the functional role of miR-145 in therapeutic resistance and the tumor microenvironment. It may serve as an innovative biomarker for therapeutic response and cancer prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available